Allarity Therapeutics (ALLR) said Thursday it reached a final settlement with the US Securities and Exchange Commission regarding the investigation into its past disclosures about interactions with the US Food and Drug Administration concerning its 2021 application for Dovitinib.
Under the settlement, which follows a preliminary agreement in January, Allarity said it agreed to an administrative cease-and-desist order without admitting or denying any wrongdoing.
The company said previously that it agreed to pay a one-time civil penalty of $2.5 million to resolve the investigation. The amount does not affect its outlook, Allarity said, adding that it continues to expect its cash position to support operations into 2026.
Shares of Allarity were up about 2% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。